Table 2.
Summary of findings from the systematic review on patient-reported outcome measures in patients with TAK
| PROM | Comparison with healthy controls | Changes over time | Comparison between patients with active and inactive disease |
|---|---|---|---|
| Quality of life | |||
| SF-36 | Worse in TAK* | Stable or better with time | Worse in active TAK* |
| Improvement following exercise therapy or infliximab | |||
| EQ-5D | – | Improve following infliximab or vascular bypass surgery | – |
| Disability | |||
| HAQ | Worse in TAK* | Stable over time/following exercise therapy/following infliximab | – |
| IPAQ-SF | Lesser physical activity in TAK* | – | – |
| WIQ | Worse in TAK* | – | – |
| WPAI | – | – | Greater work impairment in those with active disease* |
| Mood | |||
| Anxiety (HADS-A) | Worse in TAK | – | Worse in active TAK* |
| Depression (HADS-D) | Worse in TAK* | – | Worse in active TAK* |
| Fatigue | |||
| MFI-20 | – | – | – |
| Perceptions of illness | |||
| IPQ-R | – | – | – |
| BIPQ | – | – | – |
| NHP | Worse in TAK* | – | – |
| Fibromyalgia | |||
| Diagnostic criteria for fibromyalgia | Similar prevalence in TAK and HC | – | Active TAK associated with greater risk of prevalent fibromyalgia* |
PROM Patient-reported outcome measure
*Significant difference at the 5% level between comparisons